Angiodysplasia future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nikita Singh, M.B.B.S.[2]
Future or investigational therapies
Future or investigational therapies
In a study, significantly lower levels of Angiopoietin-1 (Ang-1) and TNF-α were found in patients with small bowel angiodysplasia as compared to the control group.[1] Despite similar progress in some other studies, the use of chemical markers of angiogenesis as diagnostic tool for angiodysplasia is still at an early stage and would require further research into this area.
Further insight into the pathogenesis of angiodysplasia is required for better diagnostic and therapeutic options of this condition.[2]
References
References
- â Holleran G, Hussey M, Smith S, McNamara D (2017). “Assessment of serum angiogenic factors as a diagnostic aid for small bowel angiodysplasia in patients with obscure gastrointestinal bleeding and anaemia”. World J Gastrointest Pathophysiol. 8 (3): 127â132. doi:10.4291/wjgp.v8.i3.127. PMCÂ 5561433. PMIDÂ 28868182.
- â GarcĂa-CompeĂĄn D, Del Cueto-Aguilera ĂN, JimĂ©nez-RodrĂguez AR, GonzĂĄlez-GonzĂĄlez JA, Maldonado-Garza HJ (2019). “Diagnostic and therapeutic challenges of gastrointestinal angiodysplasias: A critical review and view points”. World J Gastroenterol. 25 (21): 2549â2564. doi:10.3748/wjg.v25.i21.2549. PMC 6558444 Check
|pmc=value (help). PMIDÂ 31210709.
Looking for the patient version?
© 2026 MyEClinic â IFTM Institut fĂŒr Telematik in der Medizin GmbH